Page 112 - Read Online

Page 767 Remley et al. Cancer Drug Resist 2023;6:748-67 https://dx.doi.org/10.20517/cdr.2023.63

generation of adaptive regulatory T cells. Blood 2008;111:251-9. DOI PubMed PMC
140. Ryzhov S, Novitskiy SV, Zaynagetdinov R, et al. Host A adenosine receptors promote carcinoma growth. Neoplasia 2008;10:987-
2B
95. DOI PubMed PMC
141. Merighi S, Benini A, Mirandola P, et al. Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1α, vascular
endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol Pharmacol 2007;72:395-406. DOI
142. Wilson JM, Kurtz CC, Black SG, et al. The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell
IL-6. J Immunol 2011;186:6746-52. DOI PubMed PMC
143. Taylor CT, Colgan SP. Regulation of immunity and inflammation by hypoxia in immunological niches. Nat Rev Immunol
2017;17:774-85. DOI PubMed PMC
144. Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity 2014;41:518-28.
DOI PubMed PMC
145. Xia C, Yin S, To KKW, Fu L. CD39/CD73/A2AR pathway and cancer immunotherapy. Mol Cancer 2023;22:44. DOI PubMed
PMC
146. Fong L, Hotson A, Powderly JD, et al. Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell
cancer. Cancer Discov 2020;10:40-53. DOI PubMed PMC
147. Sitkovsky MV. Lessons from the A2A adenosine receptor antagonist-enabled tumor regression and survival in patients with
treatment-refractory renal cell cancer. Cancer Discov 2020;10:16-9. DOI PubMed
148. Bhalani DV, Nutan B, Kumar A, Singh Chandel AK. Bioavailability enhancement techniques for poorly aqueous soluble drugs and
therapeutics. Biomedicines 2022;10:2055. DOI PubMed PMC